The committee met earlier this year or late last year and asked for a price range from each manufacturer so they can start their pharmacoeconomic models
even the 200 dollars for PFE and 270 for GSK were not final numbers, but I read that GSK said they guarantee it woudl not drift above 295, PFE didn't guarantee any upper limit on price but did say it woudl likely be 270 or less
I was working today so didn't listen to the meeting
The entire thing is beyond bizarre - when you read headlines the vote was 9-5 to recommend vaccination in >65 year olds but 13-0 with one abstention for 60-64?? You would think the opposite risk benefit favors older - so the only conclusion is the 5 against in the >65 year olds wanted a universal recommendation
I have no clue how the shared decision making language could affect uptake, but it can't be good (GSK is relying on this more than PFE so another suprise is that GSK is up today on a largely down day, and now after hours no movement- so maybe i have no clue what i am talking about
Market Data 
Markets 
AI
